等位基因水平HLA配型对成人血液系统恶性肿瘤双份脐血移植结局的影响
该研究纳入2006至2019年间接受双份脐血移植的963例成人血液系统恶性肿瘤患者,按与受者差异最大的脐血单位进行等位基因水平HLA配型。0至3个错配组392例,≥4个错配组571例。≥4个错配与更差的总体生存、更高的移植相关死亡和更差的中性粒细胞恢复相关,但复发率更低,对移植物抗宿主病无显著影响。
要点
- 0至3个错配组4年总体生存为54%,≥4个错配组为43%。
- 0至3个错配组第100天和4年移植相关死亡分别为10%和23%,≥4个错配组分别为16%和36%。
- 作者认为应尽可能避免使用≥4个错配(≤4/8 HLA相合)的脐血单位。
核心结论
- 等位基因水平HLA配型是双份脐血移植后总体生存的重要因素,应尽可能避免使用≥4个错配(≤4/8 HLA相合)的脐血单位。
研究设计与样本
- 研究纳入963例接受双份脐血移植的成人血液系统恶性肿瘤患者,具备HLA-A、-B、-C和-DRB1等位基因水平配型,移植时间为2006至2019年。
- 供受者HLA配型按与受者差异最大的脐血单位进行评定。
主要发现
- 392例患者接受0至3个错配的双份脐血移植,571例接受≥4个等位基因错配的双份脐血移植。
- 0至3个错配组第100天和4年移植相关死亡分别为10%和23%,≥4个错配组分别为16%和36%。
- 更高的等位基因错配程度与更差的中性粒细胞恢复和更低的复发发生率相关,未观察到对移植物抗宿主病的显著影响。
- 0至3个错配组4年总体生存为54%,≥4个错配组为43%。
- 增加总 nucleated cell 剂量仅部分减轻了较高HLA差异相关的较差总体生存。
临床怎么用
- 作者认为应尽可能避免使用≥4个错配(≤4/8 HLA相合)的脐血单位。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In single unrelated cord blood transplantation (UCBT), an increasing number of HLA allele mismatches (MM) has been associated with inferior overall survival (OS) and attributed to higher transplant-related mortality (TRM). Previous studies on the role of allele-level HLA matching after double UCBT (dUCBT) showed conflicting results. In this study, we report the impact of allele-level HLA matching on the outcomes of a large dUCBT cohort. We included 963 adults with hematologic malignancies, with available allele-level HLA matching at HLA-A, -B, -C, and -DRB1, receiving dUCBT between 2006 to 2019. Assignment of donor-recipient HLA match was performed considering the unit with the highest disparity with the recipient. Three hundred ninety-two patients received dUCBT with 0 to 3 MM and 571 with ≥4 allele MM. For recipients of dUCBT with 0 to 3 MM, day-100 and 4-year TRM were 10% and 23%, respectively, compared with 16% and 36% for those with ≥4 MM. A higher degree of allele MM was also associated with the worse neutrophil recovery and lower incidence of relapse; no significant effect on graft-versus-host disease was observed. Patients receiving units with 0 to 3 MM had a 4-year OS of 54% compared with 43% for those receiving units with ≥4 MM. The inferior OS associated with higher HLA disparity was only partially mitigated by increased total nucleated cell doses. Our results confirm that allele-level HLA typing is a significant factor for OS after dUCBT, and units with ≥4 MM (≤4/8 HLA-matched) should be avoided if possible.
引用
- Fatobene G, Mariano L, Volt F, et al. Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies. Blood Adv. 2023. PMID: 36877784. doi:10.1182/bloodadvances.2022009251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。